Vanda Pharmaceuticals Inc. Annual Costs and Expenses in USD from 2010 to 2023

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Vanda Pharmaceuticals Inc. quarterly/annual Costs and Expenses history and growth rate from 2010 to 2023.
  • Vanda Pharmaceuticals Inc. Costs and Expenses for the quarter ending June 30, 2024 was $60.6M, a 23.9% increase year-over-year.
  • Vanda Pharmaceuticals Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $214M, a 6.2% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Costs and Expenses for 2023 was $207M, a 16.7% decline from 2022.
  • Vanda Pharmaceuticals Inc. annual Costs and Expenses for 2022 was $248M, a 9.51% increase from 2021.
  • Vanda Pharmaceuticals Inc. annual Costs and Expenses for 2021 was $227M, a 2.53% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $207M -$41.5M -16.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-08
2022 $248M +$21.5M +9.51% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-08
2021 $227M +$5.59M +2.53% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-08
2020 $221M +$16.6M +8.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-09
2019 $204M +$33M +19.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $171M -$10.6M -5.83% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $182M +$17.4M +10.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $165M +$14.5M +9.65% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-19
2015 $150M +$120M +399% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-15
2014 $30.1M -$25M -45.4% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
2013 $55.1M -$6.83M -11% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-12
2012 $61.9M +$19.9M +47.5% Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
2011 $42M +$15.1M +56.2% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-25
2010 $26.9M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.